[at Motley Fool] – A decision to put off the launch of Biogen’s (BIIB) highly anticipated launch of its MS drug Tecfidera in Europe appears to have paid off, thanks to expanded patent protection.
Read more on this.
Biogen Idec Inc. … [visit site to read more]Similar posts:
- Company Update – Biogen Idec Inc. (NASDAQ:BIIB) – Biogen wins protection for MS drug Tecfidera in Europe
- Stock Update: Biogen Idec Inc. (NASDAQ:BIIB) – December 27th Options Now Available For Biogen Idec (BIIB)
- Boeingâ€™s Double Top: Will the company continue to soar?